Site Search
Professionals 541 results
Capabilities 85 results
Practice Area
For decades, Winston has represented a broad array of clients in the insurance industry, including some of the world’s largest and best-known insurers. Our prowess in and understanding of the insurance industry encompasses not only its products, practices, and services, but also the increasing challenges posed by a world increasingly characterized by a fast-evolving technological landscape as well as financial, political, and environmental instability. Accordingly, Winston’s lawyers are among the most sought-after in the industry—not only by companies currently facing high-stakes litigations and investigations, but by those looking to take preventive action now in order to mitigate and manage their risk in the future.
Practice Area
Brands across key sectors turn to Winston litigators to defend their reputations in advertising class actions, competitor disputes, and investigations. With litigators based in the U.S.’s busiest jurisdictions—including courts in California, Florida, Illinois, New York, and Texas—we have deep experience and prowess in handling some of the most high-profile and business-essential advertising cases in recent history. These disputes have involved false advertising; unfair competition, unfair business practices, and unjust enrichment; copyright, trade name, and service mark infringement; consumer-protection claims; and violations of the Lanham Act.
Practice Area
Trial skills matter—even in a world where few disputes ever see the inside of a courtroom. Winston has built a reputation as a trial lawyers’ firm, featuring seasoned litigators who leverage extensive courtroom experience to meet our clients’ business and legal objectives. Our long history of taking cases to trial—and winning—provides our clients with tremendous settlement leverage with their adversaries, as well as a substantial likelihood of a favorable resolution if, and when, they go to trial.
Experience 37 results
Experience
|June 28, 2024
Agreement Between 119 Institutional Investors and the Company Vivendi SE
119 institutional investors, among which Union Asset Management Holding, accused the French company Vivendi of having disseminated false or misleading information between 2000 and 2002, thereby causing them an important stock market damage.
Experience
|September 1, 2023
Experience
|August 17, 2023
Winston Serves as Trial Counsel in Monsanto Roundup Litigation
Insights & News 3,565 results
Speaking Engagement
|October 17, 2024
Claire Fundakowski Presents at 2024 Hatch-Waxman and BPCIA Passport to Proficiency Series
Winston & Strawn partner Claire Fundakowski will present during ACI’s Fourth Annual Passport to Proficiency on the Essentials of Hatch-Waxman and BPCIA.
Seminar/CLE
|September 26, 2024
Public Company Priorities Breakfast or Lunch Program
Join us for Winston & Strawn’s Public Company Advisory series, where our seasoned attorneys will delve into the latest hot topics affecting Public Companies.
Sponsorship
|September 25, 2024
Winston Sponsors, Partner Speaks at IAM Live: Trade Secret Strategy USA 2024
Winston & Strawn is proud to sponsor the 2024 IAM Live: Trade Secret Strategy USA in San Francisco, CA, on September 25, 2024.
Other Results 74 results
Law Glossary
What Is Advertising Litigation?
Advertising litigation is defined as the legal area that covers false or deceptive advertising cases. Lawsuits may be brought by government agencies or corporate competitors based on the Lanham Act—a law that specifically deals with false advertising. The Act outlines how an advertisement can be deemed false. The Federal Trade Commission (FTC) has the ability to file lawsuits to halt deceptive advertising claims. The U.S. Food and Drug Administration may also pursue advertising litigation against violators of government regulations. Companies may be called on to substantiate their advertising claims, whether these are made in print or online.
Law Glossary
What Are the Patent Litigation Differences Between the BPCIA and Hatch-Waxman Act?
There are fundamental differences between the abbreviated approval processes to obtain FDA approval for biosimilars and generic drugs as those processes relate to patent litigation.